PharmiWeb.com - Global Pharma News & Resources
30-Mar-2019

Chronic Obstructive Pulmonary Disease Treatment Market to Cross $ 24.3 Billion by 2026 | CAGR: 4.9%

Recent study titled, "Chronic Obstructive Pulmonary Disease Treatment Market (By Drug Class: Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, Others; By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026" which covers detailed statistical analysis and enlightens market dynamics and trends that provide a holistic picture of the industry.

Globalchronic obstructive pulmonary disease industry sizeis anticipated to value around USD 24.3 billion by 2026. The market is foreseeable to display a CAGR of 4.9% during the coming years.

Request a Sample Copy ofChronic Obstructive Pulmonary Disease Treatment Market@https://www.acumenresearchandconsulting.com/request-sample/1145

Various market players have gotten endorsements from the Food and Drug Administration (FDA), the European Commission, and other administrative experts in the previous couple of years. These players have propelled new products, for example, triple treatment drugs and different blends in the market, empowering them to increase noteworthy market share of the overall industry. In December 2018, AstraZeneca got endorsement from the European Commission (EC) for Bevespi Aerosphere in a pressurized metered-portion inhaler (pMDI) demonstrated as an upkeep double bronchodilator treatment in grown-up patients with COPD. This endorsement empowered the organization to add its innovatively propelled item to the current item offering for patients in Europe. In December 2018, Teva Pharmaceutical Industries Ltd. gotten the U.S. Sustenance and Drug Administration (FDA) endorsement for ProAir Digihaler inhaler powder, which is a digital inhaler with inherent sensors suggested to a sidekick versatile application. This endorsement helped the organization to fortify its development abilities in respiratory consideration, in this manner accomplishing huge development in the market.

The global chronic obstructive pulmonary disease treatment market is segmented into drug class, distribution channel and region. On the basis drug class, the global chronic obstructive pulmonary disease treatment market is segmented into Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, and Others. On the basis distribution channel, the global chronic obstructive pulmonary disease treatment market is segmented into Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies. On the basis of region the global chronic obstructive pulmonary disease treatment market is bifurcated into North America, Latin America, Europe, Middle East amp; Africa, and Asia Pacific.

Based on distribution channel, the market has been arranged into retail drug stores, emergency clinic drug stores, and online drug stores. The retail drug stores segment is required to grow at the quickest CAGR because of surge in the number of patients leaning toward retail drug stores. The online drug stores section is probably going to be driven by ascend in mindfulness about these drug stores among the overall public.

On the basis of drug class, the worldwide chronic obstructive pulmonary disease treatment market has been sectioned into bronchodilators, combination, phosphodiesterase type 4 inhibitors, corticosteroids, mucokinetics, and others. The combination segment has been segmented into long acting beta agonist amp; inhaled corticosteroids (LABA-ICS), triple therapy, long acting muscarinic antagonist amp; inhaled corticosteroids (LAMA-ICS), and others. The bronchodilators segment has been bifurcated into short acting beta agonist (SABA), long acting beta agonist (LABA), and long acting muscarinic rival (LAMA). The combination segment is anticipated to represent major share of the market by 2026 because of increment in number of doctors recommending combination treatment and increase in the number of medications accessible for COPD treatment. The bronchodilators segment is foreseen to develop at a steady pace attributable to increment in the appropriation of long acting muscarinic rival (LAMA) drugs.

Browse Full Report with Table of Content, List of Table and Figures@ https://www.acumenresearchandconsulting.com/chronic-obstructive-pulmonary-disease-treatment-market

Based on the region, the worldwide chronic obstructive pulmonary disease (COPD) treatment market has been classified into Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. North America represented the biggest revenue share of the worldwide market in 2018. Presence of built up pharmaceutical organizations, increment in adoption of new drugs propelled in the market, and concentrate on dispatch of new products through Ramp;D are foreseen to drive the market in the area amid the estimate time frame.

The chronic obstructive pulmonary disease (COPD) treatment industry in Europe is driven by increment in Ramp;D spending and introduction of new products. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. gotten approval from the European Commission for extended use for once-daily Trelegy Ellipta, first single inhaler triple treatment demonstrated for COPD patients who were not enough treated with dual bronchodilation.

Increase in commonness of COPD, high environmental contamination, increment in the geriatric populace, and development of the pharmaceutical business are foreseen to fuel the development of the chronic obstructive pulmonary disease (COPD) treatment market in Asia Pacific. An article published in the International Journal of Pulmonary and Respiratory Sciences expressed that COPD is the third driving reason for death in India.

The main business working in the global chronic obstructive pulmonary disease market are Orion Corporation, AstraZeneca, Mylan N.V., Boehringer Ingelheim Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc. and CHIESI Farmaceutici S.p.A.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

CHAPTER 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DRUG CLASS

CHAPTER 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

CHAPTER 6. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

CHAPTER 7. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

CHAPTER 8. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

CHAPTER 9. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

CHAPTER 10. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

CHAPTER 11. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY

CHAPTER 12. COMPANY PROFILE

CHAPTER 13. RESEARCH APPROACH

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1145

The report is readily available and can be dispatched immediately after payment confirmation.

To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1145

Editor Details

Last Updated: 15-Apr-2019